Sartorius Stedim Biotech Partners with Sensible Biotechnologies
Sartorius Stedim Biotech, a biotechnology company, has entered into a partnership with Sensible Biotechnologies to enhance its mRNA design and manufacturing capabilities.
The partnership aims to scale up Sartorius Stedim Biotech’s cell-based technology platform.
Partnership Details
- Sartorius Stedim Biotech has partnered with Sensible Biotechnologies to develop its mRNA design and manufacturing capabilities.
- The partnership is focused on scaling up the company’s cell-based technology platform.
Financial Performance
Sartorius Stedim Biotech’s stock price has fluctuated between 143.2 EUR and 239.8 EUR over the past year. Key financial metrics include:
- Current stock price: 194.35 EUR
- Price-to-earnings ratio: 97.52
- Price-to-book ratio: 5.04